Arjo (STO:ARJO B) Third Quarter 2022 Results
Main financial results
- Revenue: 2.52 billion kr (up 12% compared to Q3 2021).
- Net income: 86.0 million kr (down 55% compared to Q3 2021).
- Profit margin: 3.4% (vs. 8.4% in 3Q 2021).
- The lower margin was driven by higher expenses.
All figures shown in the table above are for the 12 month period (TTM)
Arjo EPS does not meet expectations
Revenue is in line with analysts’ estimates.
Going forward, revenues are expected to grow by an average of 6.6% per year over the next 3 years, compared to a growth forecast of 23% for the medical equipment industry in Sweden.
Performance of the Swedish medical equipment industry.
Shares of the company are down 7.8% from a week ago.
Remember that there may still be risks. For example, we have identified 3 warning signs for Arjo which you should be aware of.
Valuation is complex, but we help make it simple.
Find out if Arjo is potentially overvalued or undervalued by viewing our full analysis, which includes fair value estimates, risks and warnings, dividends, insider trading and financial health.
See the free analysis
Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.